6.4 Surgical Interventions & Epilepsy Patient Education

Surgical Interventions & Epilepsy Patient Education

Epilepsy Surgery Evaluation

For the approximately 30% of patients with epilepsy whose seizures remain refractory despite adequate trials of at least two appropriately chosen and dosed antiepileptic drugs (AEDs), surgical intervention must be aggressively considered. Medically refractory epilepsy is associated with significant morbidity, cognitive decline, psychosocial disability, and an increased risk of Sudden Unexpected Death in Epilepsy (SUDEP).

The cornerstone of surgical evaluation is localizing the epileptogenic zone—the area of cortex that is necessary and sufficient for initiating seizures and whose removal or disconnection will result in seizure freedom. Phase I evaluation is non-invasive and includes:

• Video-EEG Monitoring: To capture typical seizures, confirm the diagnosis, and document the electrographic onset.
• High-Resolution MRI: Dedicated epilepsy protocols to identify structural lesions (e.g., mesial temporal sclerosis, focal cortical dysplasia, cavernomas).
• Neuropsychological Testing: To assess cognitive domains, establish a baseline, and identify functional deficits correlating with the suspected epileptogenic zone.
• Functional Imaging: such as PET (typically showing interictal hypometabolism) and SPECT (showing ictal hyperperfusion).
• Functional MRI (fMRI) or Wada Test: To lateralize and localize eloquent cortex (language and memory) to minimize postoperative neurological deficits.

If non-invasive testing is discordant or inconclusive, Phase II invasive evaluation is performed using subdural grids, strips, or stereoelectroencephalography (SEEG) depth electrodes placed directly on or within the brain to precisely map the seizure focus and adjacent eloquent cortex.

Resective vs. Palliative Surgery

Surgical procedures are broadly categorized as resective (curative intent) or palliative. Resective surgeries involve removing the epileptogenic tissue. The most common and successful procedure is anteromedial temporal resection (AMTR) for mesial temporal lobe epilepsy, which yields seizure freedom rates of 60-80%. Extratemporal resections (frontal, parietal, occipital) are also performed, though outcomes depend heavily on identifying a discrete structural lesion. Hemispherectomy (or functional hemispherotomy) is utilized in catastrophic catastrophic infant/childhood epilepsies involving one entire hemisphere, such as Rasmussen's encephalitis or Sturge-Weber syndrome.

Palliative surgeries aim to reduce seizure frequency or severity when resective surgery is not feasible (e.g., multifocal onset, generalized epilepsy, or overlap with eloquent cortex). Corpus callosotomy involves sectioning the corpus callosum to prevent the rapid bilateral spread of seizures; it is particularly highly effective in significantly reducing potentially injurious atonic seizures ("drop attacks").

Neuromodulation: VNS, RNS, and DBS

For patients who are not candidates for resective surgery, neuromodulation offers advanced palliative options.

• Vagus Nerve Stimulation (VNS): An implanted pulse generator delivers intermittent electrical stimulation to the left vagus nerve, which projects to the nucleus tractus solitarius and widespread cortical and subcortical areas. VNS is FDA-approved for adjunctive treatment of focal seizures. It is not typically curative but reduces seizure frequency by >50% in roughly half of patients over time.
• Responsive Neurostimulation (RNS): A "closed-loop" system where electrodes are placed at up to two epileptogenic foci. The device continuously monitors ambient EEG activity, detects specific abnormal electrographic patterns heralding a seizure, and immediately delivers targeted electrical stimulation to abort the seizure before clinical manifestations occur.
• Deep Brain Stimulation (DBS): Involves continuous or scheduled stimulation of deep brain structures. The Anterior Nucleus of the Thalamus (ANT) is the primary FDA-approved target for focal epilepsy, acting to disrupt the propagation of seizure activity through the circuit of Papez.

Patient Education: SUDEP and Pregnancy

Comprehensive patient education is a critical responsibility of the CNRN. Two paramount areas require meticulous counseling: SUDEP prevention and pregnancy management.

Sudden Unexpected Death in Epilepsy (SUDEP) is a leading cause of epilepsy-related mortality, defined as the sudden, unexpected, witnessed or unwitnessed, non-traumatic, and non-drowning death in a patient with epilepsy, with or without evidence of a seizure, where postmortem examination does not reveal a structural or toxicological cause for death. The precise mechanism is likely a combination of post-ictal respiratory depression (central apnea) and cardiac arrhythmias. The single greatest risk factor for SUDEP is the presence and frequency of generalized tonic-clonic seizures (GTCS). Other risk factors include nocturnal seizures, medication non-adherence, and a long duration of epilepsy. Counseling must emphasize that the most effective strategy to prevent SUDEP is maximizing seizure control, particularly eliminating GTCS. Patients must be educated on absolute adherence to their AED regimens, avoiding known triggers (sleep deprivation, alcohol), and considering nocturnal monitoring devices if appropriate.

Pregnancy Counseling must begin for all women of childbearing potential before conception. The overarching goal is to maintain optimal seizure control while minimizing teratogenic risk to the fetus, as maternal seizures (especially GTCS) pose significant risks to both mother and fetus (hypoxia, trauma, placental abruption, miscarriage). Key educational points include:

• Teratogenicity: Valproic acid carries the highest risk of major congenital malformations (e.g., neural tube defects) and adverse cognitive outcomes, and should be stringently avoided in women of childbearing potential unless no other option exists. Polytherapy also increases risk. Levetiracetam and lamotrigine generally have the most favorable pregnancy safety profiles.
• Folic Acid Supplementation: All women of childbearing potential with epilepsy should take daily folic acid (typically 1-4 mg/day) prior to conception and throughout the first trimester to mitigate the risk of neural tube defects.
• Pharmacokinetic Changes during Pregnancy: Renal clearance and hepatic metabolism dramatically increase during pregnancy, particularly for drugs like lamotrigine and levetiracetam. Blood volume and volume of distribution also expand. This frequently leads to a significant drop in serum AED levels, requiring frequent monitoring (e.g., monthly) and proactive dose increases to prevent breakthrough seizures. Levels typically return to baseline rapidly postpartum, requiring prompt dose reductions to avoid toxicity.
• Vitamin K: Historically, Vitamin K supplementation in the final month of pregnancy was recommended for women on enzyme-inducing AEDs to prevent hemorrhagic disease of the newborn, though modern neonatal administration of Vitamin K largely mitigates this risk.